Paraneoplastic Neurological Disease Subgroups
For the purposes of this article, PNS will be classified into four subgroups based on pathogenetic criteria.
Classical Target-oriented Immune-mediated Diseases
In neurology the classic target antibody-mediated diseases are MG, LEMS and neuromyotonia. Antibody-mediated diseases are fairly well understood, although some details are still missing. MG, which can only be considered a PNS of thyoma, has been the pattern for immune models of PNS. In MG, MuSK antibodies have been described in addition to the acetylcholinesterase antibodies, and other antibodies still may be detected in seronegative MG. LEMS is an interesting neuromuscular transmission disorder, affecting the presynaptic calcium channels. It can appear as a paraneoplastic syndrome, or as an autoimmune syndrome.
As early as 1988, O'Neill 10 reported that the ratio of incidences of neoplastic to non-neoplastic LEMS was approximately 50:50. These data seem to be confirmed by the time course and more criteria appear, which make it possible to distinguish between the two types of LEMS.
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Neuromyotonia was described by Hart et al. 4 
Surface Antibodies
Recent developments have led to the discovery of surface antigens, which act either on channels or receptors. Examples of surface 
Others
Despite the many classifications and descriptions available, several phenomena -which can be clearly described as 'paraneoplastic'
-are yet to be fully explained. Three examples include paraneoplastic neuropathy, terminal neuropathy and cancer cachexia.
Paraneoplastic Neuropathy
The PNS Euronetwork database has revealed that SSN is one of the most frequent PNS 8 and that asymmetry, onset in the upper extremities and characteristic sensory ataxia can be confirmed in most cases that are identified. A considerable number of patients with SSN (117/238) also showed motor involvement, thus prompting the introduction of the term 'sensorimotor neuronopathy'.
It remains unclear what causes this weakness: motor neurone loss or axonal degeneration.
Terminal Neuropathy
Patients with advanced cancer often develop signs of neuropathy. This has been well described as a terminal neuropathy, and consists of mild wasting of muscle, areflexia and few sensory changes. This phenomenon resembles neuropathies that occur in patients with severe disease, particularly infections, and may be caused by weight loss or unidentified metabolic factors.
Paraneoplastic Neurologic Syndromes 
in the N-methyl-D-aspartic acid (NMDA) and voltage-gated potassium channels (VGCK) types of limbic encephalitis (LE). AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; EPS = extrapyramidal signs; GABA = gamma aminobutyric acid; LE = limbic encephalitis; REM = rapid eye movement.
explanation. Many patients experience weight loss, in particular loss of muscle mass.
19 Weight loss and sarcopoenia are also increasingly observed in other generalised diseases, and these may share a common pathway. For cancer patients it has been postulated that reducing or stopping weight loss may yield a better prognosis.
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Enlarged Clinical Spectrum of Clinical Paraneoplastic Neurological Syndromes
The PNS database includes the most frequent PNS syndromes and describes large numbers of clinical characteristics for them, enabling clinicians to make judgements based on the results of a large observational study. However, the new recently described surface antibodies will increase its clinical spectrum still further.
Brain Stem Encephalitis and Ventilation
Some PNS, particularly those associated with Hu and the new surface antibodies, may have signs of brain stem encephalitis resulting in hypoventilation and even apnoea. 21 This is of practical importance in patient management and may previously have been overlooked.
The Spectrum of Paraneoplastic Psychiatric and Neurological Symptoms in Limbic Encephalitis
The characterisation of psychiatric symptoms 22 will allow for a more precise diagnosis based on clinical presentation. The core symptoms of LE are short-term memory loss and confusion (see Figure 1) . Several markers based on antibody type exist, and consist of a neurological and a psychiatric presentation. and may not only improve but even heal the patient. n Brain Trauma Oncology 
